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ABSTRACT
Success of cell replacement therapies for neurological disor-
ders will depend largely on the optimization of strategies to
enhance viability and control the developmental fate of stem
cells after transplantation. Once transplanted, stem/progen-
itor cells display a tendency to maintain an undifferentiated
phenotype or differentiate into inappropriate cell types.
Gain and loss of function experiments have revealed key
transcription factors which drive differentiation of imma-
ture stem/progenitor cells toward more mature stages and
eventually to full differentiation. An attractive course of
action to promote survival and direct the differentiation of
transplanted stem cells to a specific cell type would there-
fore be to force expression of regulatory differentiation mol-
ecules in already transplanted stem cells, using inducible
gene expression systems which can be controlled from the
outside. Here, we explore this hypothesis by employing a tet-
racycline gene regulating system (Tet-On) to drive the dif-
ferentiation of boundary cap neural crest stem cells
(bNCSCs) toward a sensory neuron fate after transplanta-
tion. We induced the expression of the key transcription fac-
tor Runx1 in Sox10-expressing bNCSCs. Forced expression
of Runx1 strongly increased transplant survival in the
enriched neurotrophic environment of the dorsal root gan-
glion cavity, and was sufficient to guide differentiation of
bNCSCs toward a nonpeptidergic nociceptive sensory neu-
ron phenotype both in vitro and in vivo after transplanta-
tion. These findings suggest that exogenous activation of
transcription factors expression after transplantation in
stem/progenitor cell grafts can be a constructive approach
to control their survival as well as their differentiation to
the desired type of cell and that the Tet-system is a useful
tool to achieve this. STEM CELLS 2009;27:1592–1603
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
The use of stem/progenitor cells is an attractive avenue for
cell replacement strategies in the treatment of neurological dis-
orders and traumatic injuries. However, to generate neurons,
and particularly of a specific desired type, from the trans-
planted stem cells still poses a significant challenge. The cur-
rent state of the art in neural stem cell transplantation is to dif-
ferentiate stem cells in vitro into the required cell type and to
subsequently transplant an enriched population of these cells
into the injured or diseased nervous system. However, this
might not be the optimal protocol for every application, since
the time window for a successful transplantation may be nar-
row for some types of stem/progenitor cells and their fate after
transplantation remains unpredictable. As a result, the trans-
planted neural stem cells survive transplantation poorly or
undergo inappropriate or incomplete differentiation [1–3]. An
alternative approach to promote differentiation of stem cells
would focus on initiating this process after transplantation.
The aim of this study was to investigate if the exogenous
induction of a key transcription factor(s) after transplantation
could be effective in inducing subtype-specific differentiation
of transplanted stem cells. Here, we explore this approach in a
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model system of boundary cap neural crest stem cell (bNCSC)
transplantation to the dorsal root ganglion (DRG) cavity.
We previously developed a method of transplantation to
the DRG cavity that allows the identification of transplanted
cells by their specific location, and demonstrated that the
transplanted sensory neurons established functional connec-
tions with the spinal cord [4–6]. When transplanted in this
system, mouse forebrain neural stem/progenitor cells (NSPCs)
predominantly differentiated into glial cells [7], while human
NSPCs differentiated into neurons, although they remained
immature for up to 3 months post-transplantation [8]. In the
present study, we prepared bNCSCs for transplantation from
the embryonic 11,5 DRGs, including the boundary cap (b), a
transient neural crest derived structure giving rise to the last
wave of DRG neurons in development [9–11]. The bNCSCs
are multipotent stem cells that have been shown to generate
sensory neurons in vitro [12, 13] and glial cells in vivo after
transplantation [14]. Here, we explore whether conditionally
induced expression of the key transcription factor Runx1 in
Sox10-expressing cells from transgenic mice can guide the
differentiation of such peripherally transplanted bNCSCs to-
ward a nociceptor neuron phenotype.
Differentiation of neural stem cells is controlled by the
combined action of external signals and sequentially
expressed transcription factors, with some of these represent-
ing master regulators [15, 16]. We chose to control Runx1
using the Sox10 pattern of expression, since Runx1 had been
suggested to play a key role in the initial stage of differentia-
tion of NCSCs into neurons [11].
Sox10 or SRY-box containing gene 10, is a high mobility
group transcription factor expressed in all neural crest (NC)
cells and is involved in several aspects of NC development
[17, 18]. Importantly, it maintains NC cell multipotency [19]
and hence, its downregulation is a prerequisite for neuronal
differentiation [20, 21]. We employed the tetracycline gene
regulating system (Tet-On) [22] for exogenous induction of
Runx1 overexpression in bNCSCs in vitro and after transplan-
tation. This approach allowed us to use Sox10-rtTA mice [23]
to specifically target Sox10-expressing cells, since only they
will respond with TRE-Runx1 activation. We find that exoge-
nous activation of Runx1 expression in Sox10 expressing
bNCSCs promotes survival and induces specific differentia-
tion toward nonpeptidergic nociceptive-type sensory neurons
in vitro and after transplantation.
MATERIALS AND METHODS
Animals and Genotyping
Sox10-rtTA2S-M2 mice, which contain a second-generation
reverse tetracycline-controlled transactivator (rtTA2S-M2)
knocked into the genomic Sox10 locus, have been previously
described along with protocols for their genotyping [23]. Trans-
genic heterozygous C57BL/6-b-actin (CAG)-enhanced green fluo-
rescent protein (EGFP) mice (Jackson Laboratories, Bar Harbor,
ME, http://www.jax.org) were used as previously described [7].
As control to exclude any doxycycline (DOX)-mediated effects
on bNCSC differentiation in the transplants, we used neuro-
spheres from ROSA26-rtTA/HPRT-IRES-EGFP mice (generated
in the Medvinsky laboratory) in which expression of EGFP was
activated by Tet-On. ROSA26-rtTA/HPRT-IRES-EGFP mice
were generated from Ainv15 embryonic stem (ES) cells [24]
These cells contain the rtTA transgene targeted into the ROSA26
locus and a homing site for a single LoxP targeting site upstream
of the HPRT locus. cDNA targeted into the homing site is driven
by a Tet-dependent promoter. The ES cell line was generated by
targeting IRES-EGFP. ES clones that showed high levels of
EGFP expression on addition of DOX were selected for blasto-
cyst injections.
For experiments aimed at evaluating postgrafting bNCSC sur-
vival and extension of the transplanted cells, embryos were
obtained by breeding heterozygous EGFP male and heterozygous
Sox10-rtTA2S-M2 (Sox10þ/rtTA) female mice. Embryos with
EGFP expression were identified using fluorescence microscopy
and genotyped for the presence of Sox10-rtTA2S-M2. All proce-
dures were approved by the Regional Ethical Committee for
Research on Animals and carried out according to the guidelines
of the Society for Neuroscience.
Culture of bNCSCs
bNCSCs were isolated in a semiclonal fashion from Sox10þ/rtTA
or from CAG-EGFP:Sox10þ/rtTA embryos on embryonic day (E)
11, as described previously [12]. Briefly, the DRGs along with
boundary caps were mechanically separated from the isolated spi-
nal cord and mechanoenzymatically dissociated using Collage-
nase/Dispase (1 mg/ml) and DNase (0.5 mg/ml) for 30 minutes at
room temperature. Cells were plated at 0.5–1  105 cells/cm2 in
N2 medium containing B27 (Gibco, Grand Island, NY, http://
www.invitrogen.com) as well as EGF and basic fibroblast growth
factor (R&D Systems, Minneapolis, http://www.rndsystems.com;
20 ng/ml, respectively). After 12 hours, nonadherent cells were
removed together with half of the medium before adding fresh
medium. The medium was changed every other day (50% of the
medium replaced with fresh medium) until neurospheres could be
observed after approximately 2 weeks of culture. Nonpassaged
neurospheres between 2 and 3 weeks in culture were used for
subsequent experiments.
Quantitative Reverse-Transcription Polymerase
Chain Reaction
Primers used were Sox10F: TCTACACTGCCATCTCTGAC (nt:
1,691–1,710) and Sox10R: CTCCTCCACTGCCAAGC (nt: 1,871–
1,887), product length 197 bp ((Acc. no. gi|149266994). EYFPF:
GACGTAAACGGCCACAAGTT and EYFPR GTCCTCCTTGA
AGTCGATGC, product length 339 bp; Runx1F: CTCTGCTCCG
TGCTGCC and Runx1R: GTCATTAAATCTCGCAACC, product
length 189 bp. Total bNCSC RNA was extracted and transcribed
with a kit (Bio-Rad, Hercules, CA, http://www.bio-rad.com) into
cDNA using random priming with MMLV reverse transcriptase.
cDNA from 5 ng of total RNA was used for each reaction and
reverse-transcription polymerase chain reaction (RT-PCR) per-
formed as described previously [25]. All data were analyzed in
Microscoft Excel.
Nucleofection of DNA and Activation of
eYFP/Runx1 Expression in Transfected Cells
We used the construct described in Figure 1D. Nucleofection of
3-weeks-old Sox10þ/rtTA neurospheres was performed with an
Amaxa Biosystems Nucleofector according to the manufacturer’s
instructions for the Optimal Nucleofector Program A33. The level
of transfection and the efficacy of the Tet-On system were
assessed by analyzing the EYFP expression in DOX (5 lg/ml)-
treated and DOX-untreated cultures. DOX was added to cultured
neurospheres 24 hours after transfection and replaced every third
day when the culture medium was changed. The EYFP fluores-
cence was monitored in an inverted fluorescence microscope. To
verify the validity of EYFP expression as a measure of Runx1
upregulation, the expression of Runx1 and EYFP in DOX-treated
and nontreated cultures was assessed with RT-PCR.
In Vitro Differentiation Assay
DOX-treated EYFP-expressing neurospheres were picked up by
pipette under the fluorescence microscope, and plated at a density
of 1.2  103 cells on a poly-D-lysine (50 lg/ml)/laminin (20 ng/
ml)-coated coverslip and maintained in Dulbecco’s modified
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Eagle’s medium-F12/neurobasal medium supplemented with N2,
B27, 0.1 mM nonessential amino acids and 2 mM sodium pyru-
vate. Nontreated neurospheres were used in parallel as control.
The medium was replenished and DOX was added every third
day. After 1 or 2 weeks, cells were fixed with 4% phosphate buf-
fered paraformaldehyde. Each experiment was repeated at least
six times.
Transplantation and Post-Grafting Treatment
Adult C3H mice (Mollegard, Denmark) were anesthetized by in-
traperitoneal injection of xylazine (RompunVR vet.; http://
www.bayer.com) and ketamine (KetaminolVR vet.; http://www.
intervet.com) (10 and 100 ng per gram body weight, respectively).
The transplantation procedure was described previously [4–7].
Briefly, the left L4 DRG was exposed via a partial laminectomy
and carefully removed, leaving the ventral root intact. Four to five
Sox10þ/rtTA bNCSC neurospheres transfected with TREbi-EYFP-
Runx1 or the same amount of neurospheres produced from
ROSA26-rtTA/HPRT-IRES-EGFP mice were placed into the
empty DRG cavity to an approximate total number of 10,000 cells/
transplant, the dorsal root and the spinal nerve were attached to the
collection of bNCSCs and the wound closed in layers.
All recipients (n ¼ 41) received daily intraperitoneal injec-
tions of cyclosporin (Sandimmun, Novartis International, Basel,
Switzerland, http://www.novartis.com; 15 mg/kg body weight).
The experimental groups (n ¼ 12) with Sox10þ/rtTA:TREbi-
EYFP-Runx1 donor cells received DOX in their drinking water
(3 g/l with 50 g/l sucrose) from the first day after surgery and
through the entire post-transplantation period while the control
group with TREbi-EYFP-Runx1 donor cells (n ¼ 6) received pure
drinking water.
In an additional experiment to evaluate transplant size and
overall survival of transplanted bNCSCs, CAG-EGFP:Sox10þ/rtTA
bNCSCs ubiquitously expressing EGFP were used (n ¼ 6 treated;
n ¼ 3 control) with the same treatment.
As a control to exclude effects from the DOX treatment
itself, we included nontransfected (wt) EGFP bNCSCs treated, or
not treated with DOX (n ¼ 3 for each group), nontransfected
sox10-rtTA treated with DOX (n ¼ 3) and ROSA26-rTA/HPRT-
IRES-EGFP treated with DOX (n ¼ 5).
For bromodeoxyuridine (BrdU) labeling, six mice with neuro-
spheres harboring Sox10þ/rtTA:TREbi-EYFP-Runx1 transgenes
were injected with BrdU intraperitoneally once every day (10
mg/ml; 200 ll) from day 1 after transplantation and for a time-
period of 2 weeks. Three of these mice were given DOX in their
drinking water from the first post-transplantion day and the other
three mice were given DOX with a delay of 1 week postgrafting.
Processing of Transplant Tissue
One month after transplantation, the animals were reanesthetized
and perfused with phosphate-buffered picric acid–formalin. The
graft sites, together with the attached dorsal root and spinal nerve,
Figure 1. Overview of experi-
ments. Sox10þ/rtTA embryos at
E11.5 (A): express Sox10 (red) in
the dorsal root ganglia (B) as well
as in newly formed boundary cap
neural crest stem cell (bNCSC) neu-
rospheres (C). The isolated bNCSCs
are transfected with the TREbi-
Runx1-eYFP vector (D) containing
a bidirectional promoter, which on
DOX treatment induces expression
of both Runx1 and EYFP. DOX-
activated expression of Runx1/
EYFP in bNCSC neurospheres (E)
two days after transfection and 1
day after DOX activation before dif-
ferentiation assay (F) and transplan-
tation (G). Nuclear labeling with
Hoechst is shown in blue. Abbrevia-
tion: DOX, doxycycline.
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as well as the corresponding part of the spinal cord were
removed, placed in cold fixative for 4 hours, and cryoprotected
overnight in phosphate-buffered saline (PBS) containing 15% su-
crose. Tissue was sectioned using a cryostat at 9 lm thickness
and stored at 20C for later immunohistochemical processing.
Immunohistochemistry
Immunolabeling was performed as described previously [26]. Pri-
mary antibodies were anti-bIII-tubulin (bTUB; mouse monoclo-
nal; Covance, Princeton, NJ, http://www.covance.com, 1:500; rab-
bit polyclonal; Covance, 1:1,000), anti-calcitonin gene-related
peptide (CGRP; rabbit polyclonal; Chemicon, Temecula, CA,
http://www.chemicon.com, 1:4,000), anti-peripherin (mouse
monoclonal; Sigma-Aldrich, http://www.sigmaaldrich.com;
1:1000), anti-glial fibrillary acidic protein (GFAP; rabbit polyclo-
nal; DAKO, Glostrup, Denmark, http://www.dako.com; 1:1,000),
anti-RET (goat polyclonal; R&D Systems, Minneapolis, MN,
http://www.rndsystems.com; 1:20), anti-Sox10 (guinea pig poly-
clonal; 1:1,000), anti-TrkA (rabbit polyclonal; Santa Cruz, CA,
http://www.scbt.com; 1:200), RT97 (mouse monoclonal; Immun-
kemi, Jarfalla, Sweden, http://www.immunkemi.se; 1:500), and
anti-P2X3 (rabbit polyclonal; Millipore, Billerica, MA, http://
www.millipore.com; 1:400), anti-EGFP (mouse monoclonal; Invi-
trogen, Carlsbad, CA, http://www.invitrogen.com, 1:400). Second-
ary antibodies (Jackson Immunoresearch Laboratories, West
Grove, PA, http://www.jacksonimmuno.com) were diluted in PBS
with 0.3% Triton X-100 and 0.1% sodium azide: AMCA-conju-
gated donkey anti-rabbit and anti-mouse, Cy3-conjugated donkey
anti-mouse, FITC-conjugated donkey anti-rabbit, TRITC-conju-
gated rabbit anti-goat. For isolectin B4 (IB4) labeling, cultures/
slides were incubated in FITC-conjugated Griffonia Simplicifolia
Agglutinin IB4 (Vector Laboratories, Burlingame, CA, http://
www.vectorlabs.com; 1:100) for 4 hours. Sections were rinsed 3
 15 minutes in PBS, (the second wash included Hoechst 33342;
11 ng/ml; Molecular Probes, Eugene, OR, http://probes.invitro-
gen.com) and then mounted in a mixture of PBS and glycerol
(1:1; v/v) containing 0.1 M propyl gallate. Incubations without
primary antibodies were performed to exclude unspecific labeling
from secondary antibodies.
In Situ Hybridization
In situ hybridization for RET mRNA was performed on DOX-
treated and DOX-untreated Sox10þ/rtTA:TREbi-EYFP-Runx1 and
Sox10þ/rtTA:TREbi-EYFP-Runx1/EGFP transplants with a RET
probe (kindly provided by Dr. Q. Ma) and according to refs. [27,
28]. The hybridization signal was detected using an alkaline
phosphatase-conjugated antibody (1:2,000; Roche, Indianapolis,
IN) and 5-bromo-4-chloro-indolyl-phosphate/nitroblue-tetrazolium
staining.
Microscopic Analysis
Immunolabeled cultures and sections were analyzed in a Nikon
Eclipse E800 fluorescence microscope. For photography, a Nikon
DXM1200F digital camera system was used. The proportion of
neuronal cells expressing subtype-specific sensory markers was
estimated in the following combinations: bTUB/IB4; peripherin/
CGRP, bTUB/RET. Cells were counted under the 20 objective
with the aid of a square ocular frame (side 0.11 mm). Neurite
outgrowth in the in vitro differentiation assay was analyzed using
a computer-based procedure [29]. Briefly, 10 photographs (20
objective) were taken of bTUB-labeled cultures (n ¼ 6 treated; n
¼ 6 control) and placed in a grid frame on the computer screen.
The number of intersections between neurites and grid lines in
relation to the number of cells within the frame was analyzed and
used as a measure of neurite outgrowth/cell.
Every sixth slide from transplants with Sox10þ/rtTA:TREbi-
EYFP-Runx1 and ROSA26-rtTA/HPRT-IRES-EGFP neurospheres
was immunostained and cells containing nuclei were analyzed
under the 20 objective with the aid of a square ocular frame
(side 0.11 mm). For the combination IB4/CGRP/RT97 the num-
ber of cell bodies labeled with either one of these markers was
counted. For evaluation of transplant size and bNCSC survival,
every fifth section from EGFP transplants was photographed. The
NIH software ImageJ (Rasband, 1997, available at http://rsb.info.
nih.gov/ij) was used to measure transplant areas. The transplant
volume estimate was calculated according to the formula A ¼
TK[
P
(S1 to Sn)], where T is the thickness of the section (T ¼
9 lm), K is the number of sections between the measured areas
(K ¼ 5) and S is the area of the transplant on the sections from
1 to N. To generate three-dimensional images of transplants,
serial sections from transplants with eGFP expressing donor cells
were photographed and digitalized (see earlier), manually aligned
in Photoshop, and processed with the VolView 2.0 software
(KitWare, Clifton Park, NY).
For an estimate of the cell numbers in each transplant,
EGFPþ cells with nuclei were counted in every fourth section.
To correct for possible differences in nuclear size in different
transplants, the average nuclear diameter was analyzed by mea-
suring 30 randomly selected nuclei. The number of neurons
counted was multiplied by section separation to give a total esti-
mated number of profiles (n). This number was multiplied by sec-
tion thickness (T), divided by T plus the average diameter of the
nuclei (D) to give the neuronal number (N); n ¼ n  T/(T þ D)
[30, 31].
Statistics
Data were analyzed using a two-tailed unpaired Student’s t test.
RESULTS
Sox10 Expression in bNCSCs In Vitro
An overview of the experimental setup is shown in Figure 1.
The bNCSC neurospheres were produced from Sox10þ/rtTA
mouse embryos. Consistent with previous results [20], immu-
nohistochemical analysis showed that Sox10 was expressed in
E11 DRGs of Sox10þ/rtTA mice (Fig. 1B). Sox10 expression
was also found in newly formed bNCSC neurospheres (Fig.
1C) and the expression with regards to passage and days in
culture was assayed by RT-PCR (supporting information Fig.
1). As seen by RT-PCR Sox10 was initially highly expressed,
but this expression declined after 4 to 5 weeks in culture.
Thus for the experiments of this study we did not use
bNCSCs older than 3 weeks. To evaluate the expression of
transgenic Runx1 in DOX-activated neurospheres, we per-
formed RT-PCR and confirmed that the expression of Runx1
in DOX-activated neurospheres paralleled the time course of
EYFP fluorescence (supporting information Fig. 2).
Differentiation of Sox101/rtTA:TREBi-Runx1-EYFP
bNCSCs In Vitro
We next assessed how forced Runx1 expression influences the
differentiation of bNCSCs in vitro. We first analyzed the level
of EYFP expression in transfected bNCSC neurospheres to
determine the level of transfection and DOX-induced tran-
scription. Sox10þ/rtTA neurospheres were transfected with the
TREbi-Runx1-EYFP expression vector (Fig. 1D). The cells
were divided in two groups and DOX was added to the me-
dium of one of these groups 24 hours after transfection. The
expression of Runx1 in DOX-treated and control neurospheres
was monitored by the concomitant induction of EYFP expres-
sion from the bidirectional TRE promoter (Fig. 1E, 1F).
EYFP fluorescence was observed in around 60% of the DOX-
treated neurospheres, after 24–48 hours of DOX administra-
tion (supporting information Fig. 2). The percentage of
EYFP-expressing cells in individual neurospheres varied
between approximately 10% and 90%. In DOX-untreated
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www.StemCells.com
neurospheres, the expression of EYFP was extremely low and
detected only in about 0.3%–1% of the total number of cells.
EYFP/Runx1 expression in DOX-treated neurospheres gradu-
ally declined in intensity and disappeared after 2–3 weeks in
culture which is in agreement with the cessation of Sox10
expression (data not shown).
Neurospheres were plated on D-polylysine-laminin coated
coverslips 2 days after transfection in a medium without mito-
gens to allow for differentiation. No neurotrophic factors were
added to decrease the risk of a Runx1-mediated effect being
masked by differentiation directed by extrinsic factors. DOX
was added in the treated group throughout the experiment and
EYFP expression was monitored. The EYFP expression rap-
idly declined in differentiating cells (supporting information
Fig. 3). However, in a few cells it was retained for up to 2
weeks, possibly due to rare and random stable integration
events leading to poor inactivation of the Tet-promoter once
activated. This time frame of 2 weeks allowed us to visualize
the gradual differentiation of EYFP-expressing bNCSCs to
cells with a typical DRG neuron morphology (supporting in-
formation Fig. 4).
Cultures were fixed at the end of the experiment (2
weeks) and labeled with markers for sensory neuron subtypes,
with particular focus on DRG neurons previously reported to
Figure 2. DOX-activated Runx1 expression induced differentiation of boundary cap neural crest stem cells to dorsal root ganglion neurons in
vitro. DOX-induced expression of Runx1 leads to significantly increased neurite outgrowth. DOX-treated (A) and control (B) cultures, quantified
in (C; p ¼ 3.6  108). Panels (D), (F), and (H) show DOX-treated cultures to the left and DOX-untreated cultures to the right of the graphs.
The quantitative analyses of DOX-treated and DOX-untreated cultures are shown in graphs (E), (G), and (I). RET expression is induced in bIII-
tubulin (bTUB)þ cells in DOX-treated, but not in DOX-untreated cultures (panel D; quantified in E) (p ¼ 1.8  104). Also isolectin B4 binding
by bTUBþ cells was induced in DOX-treated, but not in DOX-untreated cultures (panel F; quantified in G) (p ¼ 3.6  106). Conversely, there
was no significant difference in calcitonin gene-related peptide-labeled cells in DOX-treated compared with DOX-untreated cultures (panel H;
quantified in I) (p ¼ .21). Scale bar ¼ 100 lm. Abbreviation: DOX, doxycycline.
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be Runx1-dependent. During early development, Runx1 is
expressed in the largest subpopulation of DRG neurons, the
small diameter nociceptive class [26, 32]. In addition, Runx1
has been reported to induce neurite outgrowth from DRG neu-
rons [32]. In agreement with these findings, we found that
DOX-induced Runx1 expression increased neurite outgrowth
in bTUBþ cells in culture (Fig. 2A, 2B; quantified in c; p ¼
3.6  108). Looking at the subtype markers, we found abun-
dant induction of the markers IB4 and glial cell line-derived
neurotrophic factor (GDNF) family coreceptor RET in the
DOX-treated cultures, while they were completely absent in
the control group (Fig. 2D–2G; in (e) p ¼ 3.6  106 and (g)
p ¼ 1.8  104). These markers are characteristic for non-
peptidergic nociceptor DRG neurons. In contrast, CGRP, a
marker for small peptidergic nociceptive neurons, showed no
obvious difference between DOX-treated and control cultures
(Fig. 2H, 2I; p ¼ .21). These data suggest that ectopic expres-
sion of Runx1 is sufficient to drive differentiation of bNCSCs
toward nonpeptidergic DRG neurons in the absence of neuro-
trophic factors in vitro.
Differentiation of Sox101/rtTA:TREBi-Runx1-EYFP
bNCSCs After Transplantation
After determining that forced overexpression of Runx1 in
Sox10-expressing bNCSCs in vitro can induce differentiation
toward the nonpeptidergic nociceptor phenotype, we exam-
ined whether this could also influence their differentiation in
vivo after transplantation. To this end, we used TREbi-Runx1-
EYFP transfected neurospheres, taken from cultures in which
DOX-induced EYFP expression had been confirmed in sam-
ples (the grafted cells however, had not been treated with
DOX prior to transplantation), in a transplantation experiment.
The left L4 DRG was removed and the transfected bNCSCs
were grafted in its place with nerve root endings being reat-
tached to the graft. One group of graft recipients received
DOX in their drinking water whereas the control group
received tap water. One month later, the L4 cavity containing
the grafted cells was harvested for further investigation.
We first estimated the relative extent of neuron versus
glial differentiation in DOX-treated and control transplants,
using immunohistochemistry for bTUB and GFAP in combi-
nation with nuclear counterstaining (Fig. 3A–F). The propor-
tion of bTUBþ cells was higher in DOX-treated transplants
(although not significantly, p ¼ .08) whereas that of GFAPþ
cells was significantly higher compared with DOX-untreated
transplants (p ¼ 4.7  104). In DOX-untreated transplants,
in contrast, the proportion of bTUB/GFAP negative cells was
greater (Fig. 3I, p ¼ 1.6  105).
To assess the influence of DOX treatment on neurite out-
growth from the transplanted cells, we analyzed transplants,
dorsal roots associated with the transplanted tissue, and corre-
sponding areas (L4 and L5) in the spinal cord of DOX-treated
and DOX-untreated EGFP/Sox10-rtTA2S-M2 (Sox10þ/rtTA)
mice DOX-treated Runx1-induced EGFPþ cells displayed a
more mature morphology than DOX-untreated cells (Fig. 3G,
3H) and showed extensive neurite outgrowth into the host
dorsal roots (Fig. 3I, 3J). However, neurites extending from
DOX-treated transplants did not fully reach the host spinal
cord.
We next characterized the neuronal phenotypes in trans-
plants from DOX-treated and nontreated recipients, using sen-
sory neuron subtype-specific markers. Transplants from DOX-
treated mice were characterized by an increase in IB4-labeled
(nonpeptidergic) cells (Fig. 3G, 3H, 3J; p ¼ .005). The per-
centage of cells immunoreactive for RT97 (antibody labeling
the phosphorylated form of neurofilament heavy-chain specific
for mechanosensitive cells) was significantly decreased (Fig.
3J; p ¼ .002). The percentage of CGRPþ cells also showed a
decreasing trend, but was not shown to be significant (Fig. 3J;
p ¼ .31). We also investigated the expression of TrkA and
RET in the bTUBþ cells in transplants from DOX-treated
and control mice (Fig. 4). The amount of cells expressing
both markers was significantly increased in DOX-treated
transplants (Fig. 4 C and 4F; p ¼ .003 and p ¼ 3.4  107,
respectively). Extensive expression of RET in DOX-treated
transplants was confirmed by in situ hybridization for RET
mRNA (Fig. 4D). However, while TrkA was mostly
expressed in non-neuronal bTUB-negative cells (Fig. 4A, 4B)
the majority of RET-expressing cells were bTUBþ (Fig. 4D,
4E). In addition, we assayed for the presence of the ATP re-
ceptor P2X3 which is expressed in a subset of the non-pepti-
dergic nociceptive neurons [33] that expresses Mas-related G
protein-coupled receptor D and peripherin and innervates the
superficial layers of the skin [34]. P2X3 was increased in the
neuronal (bTUBþ) population by the induction of Runx1
expression (Fig. 5A–C; p ¼ 1.3  104). The relative propor-
tion of P2X3-expressing cells was smaller than the fraction of
RET-expressing cells suggesting that, similar to the normal
DRG, only a subset of the RETþ cells express P2X3 (Figs.
4F, 5C). These data suggest that using the DOX-inducible
system to overexpress Runx1 in Sox10þ bNCSCs increases
the differentiation into a non-peptidergic nociceptive pheno-
type, possibly at the expense of other sensory neuronal cell
types. After BrdU pulse labeling in the early post-transplanta-
tion period, some RET-expressing neurons were also BrdUþ
indicating that this population indeed originated from prolifer-
ating bNCSCs (Fig. 4D).
To asses the effect of DOX treatment on transplant sur-
vival and differentiation, we transplanted nontransfected
CAG-EGFP/Sox10-rtTA, Sox10-rtTA, and ROSA26-rtTA/
HPRT-IRES-EGFP bNCSC neurospheres. We found no differ-
ence in survival and differentiation between DOX-treated
nontransfected transplants and ROSA26-rtTA/HPRT-IRES-
EGFP treated with DOX compared with the DOX-untreated
Runx1 transfected group (supporting information Fig. 8) Par-
ticularly striking was the complete absence of RET (support-
ing information Fig. 8) and P2X3 expressing cells in the con-
trol groups.
Survival of CAG-EGFP:Sox101/rtTA:
TREBi-Runx1-EYFP bNCSCs After Transplantation
To evaluate transplant size and overall survival of trans-
planted bNCSCs as well as to rule out any contribution of
endogenous cells to sensory neurogenesis, we generated
bNCSCs from CAG-EGFP:Sox10þ/rtTA mouse embryos
(ubiquitously expressing EGFP in all cells), transfected them
with the TREbi-Runx1-EYFP construct and transplanted them
to the L4 DRG cavity as described earlier. The mean volume
of DOX-treated transplants was 2.3 times larger than control
(Fig. 6A, 6B; p ¼ 5.5  104) and the total number of EGFP
expressing cells in DOX-treated transplants was increased
by 204% compared with control transplants (Fig. 6C; p ¼
1.4  104).
DISCUSSION
In this study, we have shown that differentiation of bNCSCs
towards subtype-specific sensory neuron phenotypes can be
guided in vitro and after their engraftment into the DRG cav-
ity with the Tet-On system.
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For producing bNCSCs, we used DRGs and dorsal roots
of 11.5-day old mouse embryos. At this stage, contaminating
DRG progenitor cells are still present in the DRGs, but they
cease to proliferate around E12 [35, 36]. The boundary cap
cells proliferate throughout the entire embryogenesis [37],
migrate to the DRGs and contribute to some trunk sensory
neurons, satellite cells and Schwann cells [10, 12] It was
shown previously that a rapidly amplifying population that
could not be sub-cloned, (i.e., the non-stem cell DRG progen-
itor cells mentioned above) is lost at around 6–8 days of cul-
ture of boundary cap cells whereas after about 2 weeks of
culture a more slowly dividing cell population appears that
forms neurospheres and can be repeatedly subcloned without
affecting its pluripotency [12]. Furthermore, it was shown that
Figure 4. Immunostainings and quantification of TrkA and RET in transplants. Staining for bTUB (red) and TrkA (green) show an increased
number of TrkAþ cells after DOX treatment (panel A) when compared with the control (panel B). Some TrkA is expressed in bTUBþ cells but
most TrkA staining is associated with bTUB negative cells. (C): Quantification of the increase of TrkA positive cells among the bTUBþ popula-
tion (p ¼ .0034). Staining of RET (red) in DOX-treated (panel D) and DOX-untreated (panel E) transplants. In DOX-treated transplants, the ma-
jority of RET expression (panel D; red) is associated with bTUBþ (green) cells. In situ hybridization for RET mRNA shows extensive labeling
in DOX-treated (panel D), and absence of labeling in DOX-untreated (panel E) transplants. BrdU-labeled cells, some of which express RET are
shown in panel D (right). (F): Quantification of immunolabeled cells (D, E) showing the almost complete absence of RET positive cells in the
control (p ¼ 3.4  107). Nuclear labeling with Hoechst is shown in blue. Scale bar (E) ¼ 50 lm. Abbreviations: bTUB, bIII-tubulin; BrdU,
bromodeoxyuridine; DOX, doxycycline.
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the DRG itself does not significantly contribute to neuro-
sphere formation and that the bNCSCs (as well as the actual
boundary cap cells in vivo) express Krox20, Sox10, and the
multipotency marker SSEA-1, which is not the case for sur-
rounding cell types [12, 13]. The BrdU labeling of neurons
expressing the nociceptor-specific marker RET shows the
presence of stem/progenitor boundary cap cells that continue
to divide after transplantation. As the experiments in this
study were performed with cells isolated in semiclonal condi-
tions, however, it cannot be entirely excluded that a minority
of cells in the bNCSC-population are indeed nonproliferative
committed progenitors and that a small part of the effect
might be attributed to selection in addition to the instructive
role of Runx1.
In contrast to previously transplanted neurospheres
derived from mouse [7] and human [8] forebrain, which did
not express any specific neuronal markers after transplanta-
tion, in the experiments described here, we achieved
Figure 5. Immunostainings and quantification of the ATP receptor P2X3 in transplants. Staining for bTUB (red) and P2X3 (green) shows an
increased number of P2X3þ cells after DOX treatment (A) when compared with the control (B). (C): Quantification of the increase of positive
cells among the bTUBþ population (p ¼ .0034; n ¼ 6). Scale bar (B) ¼ 50 lm. Abbreviations: bTUB, bIII-tubulin; DOX, doxycycline.
Figure 6. Increased graft size and
cell survival after DOX-induced
Runx1 expression. (A): Example of
three-dimensional reconstructions of
grafts of C57BL/6-b-actin (CAG)-
eGFP:Sox10þ/rrTA boundary cap
neural crest stem cells. (B): Quanti-
fication of graft size showing the
relative increase in size after Runx1
overexpression (p ¼ 5.5  104; n
¼ 4). (C): Quantification of eGFPþ
graft cell numbers showing an
increased survival after 1 month in
treated versus control (p ¼ 1.4 
104, n ¼ 4). Abbreviations: DOX,
doxycycline; eGFP, enhanced green
fluorescent protein.
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differentiation of transplanted cells into neurons with exten-
sive neurite outgrowth into the host dorsal roots and the
expression of neuronal markers specific for the nociceptor
neuron phenotype. Furthermore, DOX-treated recipients dis-
played increased graft size and cell survival. In vivo, a combi-
nation of intrinsic and extrinsic factors influences survival and
differentiation of transplanted cells. Survival and differentia-
tion of TrkA-expressing cells are dependent on nerve growth
factor (NGF), whereas RET-expressing cells rely instead on
members of the GDNF family [38, 39]. Differentiating imma-
ture sensory neurons may provide paracrine neurotrophic sup-
port in the transplant [40]. Non-neuronal cells, particularly
from the host, are likely to be a major source of growth pro-
moting factors, including NGF and GDNF [41, 42]. In collab-
oration with the Runx1-induced ectopic expression of the
growth factor receptors TrkA and RET, these extrinsic factors
may significantly contribute to survival and possibly also to
differentiation of the DOX-treated, transplanted bNCSCs. Fur-
thermore, recent studies have demonstrated that NGF pro-
motes differentiation and maturation of nonpeptidergic neu-
rons through both RET-dependent and RET-independent
signaling mechanisms, possibly via Runx1 expression [39].
Specifically, we could observe upregulation of P2X3 in the
transplants arguing that RET-independent markers are induced
via the Runx1 pathway. This, in conjunction with the strong
upregulation of RET would suggest that both types of non-
peptidergic genes are controlled by the Runx1 overexpression.
Compared with control transplants, we observed a signifi-
cant increase in the number of TrkAþ cells as well as a
reduction in the numbers of cells not expressing bTUB or
GFAP in DOX-treated transplants, suggesting that Runx1
overexpression might be sufficient to drive initial differen-
tiation. However, in the absence of a robust increase in the
proportion of bTUBþ cells, our data suggest that this differ-
entiation of grafted bNCSCs is to a large part glial. This is
in accordance with previous in vitro data on Runx1 overex-
pression in bNCSCs promoting survival and neuronal matu-
ration but not neurogenesis per se [32]. The same study
showed that Runx1-induced cell survival of bNCSC-derived
neurons is NGF-independent arguing for a more general
effect of Runx1 on cell survival. However, since the grafted
cells differentiate into more than one cell type it is not possi-
ble to discern between cell-autonomous effects of Runx1 and
those involving signaling between the various differentiating
cells in the transplant or with host cells. It is also possible
that the increased amount of GFAPþ cells in the Runx1-
overexpressing grafts may contribute to maintaining survival
of neighboring neuronal precursors, reminiscent of the
relationship between satellite cells and neurons in intact
DRGs [43].
In the chick, it has been suggested that Runx1 directly
activates TrkA transcription and that Runx1 overexpression in
progenitors in vivo induces ectopic expression of TrkA [32].
In the same study, siRNA knock-down of early Runx1 expres-
sion as well as overexpression of a general dominant-negative
Runx protein was shown to down-regulate TrkA expression
and cause the subsequent death of the neurons. This suggests
that Runx1 might have an effect on early progenitors by
inducing TrkA expression in DRG precursors. There seems to
be conflicting data with regards to an early role of Runx1 in
the development of nociceptive sensory neurons since there is
no loss of TrkAþ neurons in mice that lack Runx1 expression
in DRG cells [26, 44]. Our findings indicate that ectopic
Runx1 expression indirectly influences the survival of
bNCSCs grafted into the DRG cavity.
The role of Runx1 in later stages of differentiation of
DRG neurons has been convincingly demonstrated. Mice that
lack Runx1 function selectively in the peripheral nervous sys-
tem have an impaired perinatal switch from TrkA to RET of
non-peptidergic nociceptors [45]. Indeed, in the mouse, from
E14.5 to parturition, Runx1 expression is restricted to TrkAþ
neurons, but by postnatal day 30, Runx1þ neurons are TrkA-
negative and RETþ [26]. These two studies also show that
Runx1 controls, via both repressing and activating gene
expression, several aspects of maturation of nonpeptidergic
neurons such as the concerted expression of specific ion chan-
nels and receptors. This includes the expression of the ATP-
receptor P2X3. Indeed, after forced Runx1 expression, we
observed a selective up-regulation of RET, IB4-binding, and
P2X3 in differentiated bTUBþ neurons, as well as a decrease
of RT97 and CGRP expression in the transplants.
The possibility that increased survival and differentiation
to the specific type of neurons in the transplants was rather
due to the DOX-treatment or to the electroporation procedure
itself [46] was ruled out by the fact that none of the control
transplants displayed any presence of nociceptor-specific
markers. The latter appeared exclusively in Sox10-expressing
cells that were transfected with an inducible Runx1 construct
and treated with DOX. In agreement with this more mature
and differentiated phenotype, DOX-treated Runx1-induced
EGFPþ transplants displayed extensive neurite outgrowth to
the dorsal roots towards the spinal cord.
Our data show that exogenously induced Runx1 expres-
sion does not affect the relative neuron/glia proportion in the
transplants. There was a trend towards neuronal differentiation
in DOX-treated transplants but the difference was not signifi-
cant compared to DOX-untreated recipients. This finding sug-
gests that the decision of neural progenitors to become neuro-
nal or glial is regulated by other transcription factors in
bNCSCs when they still express Sox10. The large proportion
of RETþ cells is a bit surprising but might be due to a com-
bination of RET being directly downstream of Runx1 [39]
and that there is positive selection for bNCSCs that have been
transfected and express Runx1.
The Sox10þ/rtTA/TRE-Runx1 system used here appears
to be sufficient to ensure advanced cell differentiation towards
nociceptor subtype in vitro and in the transplants. The mecha-
nism for this might be due to the specific targeting of Sox10-
expressing cells for Runx1 overexpression. It was achieved by
a new approach using the Tet-On system. The separation of
the rtTA2S-M2 and TRE expressing vectors might serve as a
useful tool to specifically target certain cell types for expres-
sion of the desired key transcription factor. It also gave us the
possibility to mimic the normal cellular development pattern,
in which the expression of the transcription factor Sox10 pre-
cedes that of Runx1, a temporal sequence which seems to be
crucial for the guiding the differentiation of bNCSCs toward
nociceptive-type sensory neurons.
CONCLUSION
Our results demonstrate that using the Tet-system to exoge-
nously control Runx1 expression in grafted bNCSCs resulted
in their long-term survival, increased neurite outgrowth, and
selective differentiation of the neuronal population toward a
nonpeptidergic nociceptive neuronal phenotype. These results
are achieved by cooperation between Runx1-induced intrinsic
factors and extrinsic factors from the host environment. Our
data suggest that the Tet-system can be successfully used in
vivo to manipulate gene activation in transplanted cells.
Hence, it is reasonable to speculate that timely activation to
appropriate expression levels of just a few key transcription
Aldskogius, Berens, Kanaykina et al. 1601
www.StemCells.com
factors, specific for a certain type of stem/progenitor cell,
would be sufficient to control survival and to guide the differ-
entiation of transplanted cells to a desired cell type. Combin-
ing different Tet-system transactivators could allow the induc-
ible expression of two genes [47] or, alternatively, the
Tet-system could be used in combination with other condi-
tional gene expression systems in mice [48, 49]. Concomitant
or sequential expression of one or more key proteins can thus
be implemented for directed differentiation of stem/progenitor
cells, thus offering exciting new possibilities in understanding
development and for treating diseases.
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